Quick Takeaways
- Affinity Asset Advisors, LLC filed SCHEDULE 13G for SUTRO BIOPHARMA, INC. Common Stock, par value $0.001 per share (STRO).
- Disclosed ownership: 7.8%.
- Date of event: 16 Oct 2025.
Affinity Asset Advisors, LLC - 16 Oct 2025 SCHEDULE 13G Report for SUTRO BIOPHARMA, INC. Common Stock, par value $0.001 per share (STRO)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Healthcare Fund, LP
- Symbol
- STRO
- Shares outstanding
- 84,733,230 shares
- Disclosed Ownership
- 6,583,772 shares
- Ownership
- 7.8%
- Form type
- SCHEDULE 13G
- Filing time
- 23 Oct 2025, 16:07:17 UTC
- Date of event
- 16 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Affinity Asset Advisors, LLC disclosed 7.8% ownership in SUTRO BIOPHARMA, INC. Common Stock, par value $0.001 per share (STRO) on 16 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Oct 2025, 16:07.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Healthcare Fund, LP | 7.8% | 6,583,772 | 0 | 6,583,772 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer | |
| Affinity Asset Advisors, LLC | 7.8% | 6,583,772 | 0 | 6,583,772 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer |